Veracyte Inc
$ 35.69
-0.17%
24 Feb - close price
- Market Cap 2,821,265,000 USD
- Current Price $ 35.69
- High / Low $ 36.33 / 35.28
- Stock P/E 93.92
- Book Value 15.91
- EPS 0.38
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 50.71
- 52 Week Low 22.61
About
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$47.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-11-04 | 2025-08-06 | 2025-05-05 | 2025-02-20 | 2024-11-06 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 0 | 0.51 | 0.44 | 0.31 | 0.36 | 0.19 | 0.07 | -0.02 | -0.39 | -0.41 | -0.12 | -0.11 |
| Estimated EPS | 0.3928 | 0.32 | 0.11 | -0.17 | 0.2571 | 0.03 | -0.02 | -0.16 | -0.09 | -0.15 | -0.15 | -0.13 |
| Surprise | -0.3928 | 0.19 | 0.33 | 0.48 | 0.1029 | 0.16 | 0.09 | 0.14 | -0.3 | -0.26 | 0.03 | 0.02 |
| Surprise Percentage | -100% | 59.375% | 300% | 282.3529% | 40.0233% | 533.3333% | 450% | 87.5% | -333.3333% | -173.3333% | 20% | 15.3846% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VCYT
2026-02-24 13:52:24
Veracyte (Nasdaq: VCYT) will present over 15 abstracts at the 2026 ASCO Genitourinary Cancers Symposium, highlighting its Decipher and TrueMRD genomic tests for prostate and bladder cancers. These studies demonstrate how Veracyte's platform aids clinical decision-making, advances biological understanding, and drives innovation in urologic cancer care through real-world data and insights from phase II trials. Key presentations will focus on using genomic subtyping to inform bladder cancer treatments and the application of whole-genome sequencing for minimal residual disease detection.
2026-02-21 13:30:48
Veracyte Inc (NASDAQ:VCYT) is presented as a strong "Growth at a Reasonable Price" (GARP) stock due to its significant growth in earnings and revenue, coupled with a sensible valuation compared to biotechnology peers. The article highlights the company's robust balance sheet, featuring no debt and strong liquidity, contributing to a lower financial risk profile. Veracyte's profitability is also noted as improving and acceptable, reinforcing its position as a sound investment for growth-oriented investors.
2026-02-21 12:43:48
Jupiter Asset Management Ltd. has acquired a new position of 394,963 shares in Veracyte, Inc. (NASDAQ:VCYT) during Q3, valued at approximately $13.56 million. Veracyte currently holds a consensus "Moderate Buy" rating from analysts with an average price target of $46.14, despite recent insider share sales totaling $2.68 million. The biotechnology company focuses on genomic diagnostics to improve diagnostic accuracy and patient care.
2026-02-19 21:56:36
Veracyte, Inc., a leading cancer diagnostics company, announced its participation in two upcoming investor conferences: the Raymond James 47th Annual Institutional Investors Conference on March 3rd and the Leerink Partners Global Health Conference on March 9th. The company will provide live audio webcasts of its presentations on its investor relations website, with replays available for 90 days. This press release also includes information about Veracyte's mission to transform cancer care and details about its recent financial results and upcoming earnings release.
2026-02-18 10:39:00
OPKO Health (OPK) is positioned for growth in 2026, driven by its flagship product RAYALDEE and strategic partnerships, including an expanded agreement with Entera Bio for an oral PTH analog and a collaboration with Regeneron Pharmaceuticals. The company is also advancing several clinical trials for multispecific antibodies and vaccines. Despite these growth factors, concerns remain regarding stiff competition and an overreliance on RAYALDEE for revenue.
2026-02-18 09:27:23
The Illinois Municipal Retirement Fund recently acquired a new position in Veracyte, Inc. (NASDAQ: VCYT), purchasing 40,318 shares valued at approximately $1.38 million. This move is part of broader institutional interest, with other major investors like Artisan Partners, State Street, Bank of America, and Qube Research & Technologies Limited also increasing their stakes in the biotechnology company. Despite significant insider selling over the past quarter, analysts have generally given Veracyte a "Moderate Buy" consensus rating with an average target price of $46.14.
